Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma
Status:
Withdrawn
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The primary aim of this study is to determine the presence of gemcitabine in childhood
diffuse midline gliomas (DMG) (previously classified as diffuse intrinsic pontine glioma
[DIPG]) after systemic treatment with the drug.